At a glance
- Originator Taro Pharmaceutical Industries
- Class Antiepileptic drugs; Barbiturates; Neuroprotectants
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy; Essential tremor; Myoclonus; Neurological disorders
Most Recent Events
- 22 Sep 2010 Taro Pharmaceutical Industries has been acquired by Sun Pharmaceutical Industries
- 10 Dec 2009 No development reported - Preclinical for Neurological disorders in Canada (PO)
- 10 Dec 2009 No development reported - Phase-I for Epilepsy in USA (PO)